Home › NDC Lookup › Ingredients › Scopolamine › 70771-1787-04
Scopolamine 1 mg/3d Patch, Extended Release — NDC 70771-1787-04 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Scopolamine 1 mg/3d Patch, Extended Release — NDC 70771-1787-4 (Billing 70771-1787-04)

by Zydus Lifesciences Limited · 4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 3 d in 1 PATCH

This is a package of Scopolamine 1 mg/3d Patch, Extended Release from Zydus Lifesciences Limited, marketed since Sep 2024 and currently FDA-listed.

NDC 70771-1787-04
🏷️ FDA NDC (as labeled) 70771-1787-4 billing pads the package segment with a zero
This package
Contains3 d in 1 patch Pack sizes3 compare ↓
Also priced by: Part D plans $8.13/unit — full pricing hub ↓
Product page 70771-1787-02 Also comes in: 10 patches 70771-1787-2 24 patches 70771-1787-7
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 70771-1787-4 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
70771 labeler · 1787 product · 4 package
Package marketed since
Sep 5, 2024
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 7077117874 2
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70771-1787-4
Product NDC 70771-1787
11-digit billing NDC 70771178704
RxCUI 226552
UNII DL48G20X8X
Application # ANDA217893
SPL Set ID 016df9f3-61d5-45e9-b1d6-791a5d2f26d5
Established class (EPC) Anticholinergic
Mechanism of action Cholinergic Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-09-05
Route TRANSDERMAL
Dosage form PATCH, EXTENDED RELEASE
Substance SCOPOLAMINE
TE code (Orange Book) AB · RLD · RS
Quick answers
  • RxCUI (RxNorm): 226552
Why two NDCs? The FDA registers this code as 70771-1787-4 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70771-1787-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Anticholinergic class.

Pharmacologic class Anticholinergic
Drug family (ATC) Other antiemetics, Other hypnotics and sedatives, Anticholinergics
How it works Cholinergic Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📖 What it is MedlinePlus · NLM

Scopolamine is used to prevent nausea and vomiting caused by motion sickness or medications used during surgery. Scopolamine is in a class of medications called antimuscarinics. It works by blocking the effects of a certain natural substance (acetylcholine) on the central nervous system.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Apply it to the hairless skin directly behind one ear — that flat area just behind the earlobe. Either side works fine. The key is that the skin is clean, dry, and hair-free so the...
  • Where exactly do I put the patch, and does it matter which side?
  • Put it on at least 4 hours before you need it to be working — so if you're boarding a cruise ship in the morning, apply it the night before. The patch takes several hours to build...
  • How soon before a trip should I put the patch on?
📖 Read our full Scopolamine Transdermal Patch guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $8.13 $32.52 / 4 patch
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70771-1787-02 70771-1787-2 Main listing 10 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 3 d in 1 PATCH 2024-09-05 — Active
70771-1787-04 You're viewing this 4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 3 d in 1 PATCH 2024-09-05 — Active
70771-1787-07 70771-1787-7 24 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 3 d in 1 PATCH 2024-09-05 — Active

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 4 pouch in 1 carton / 1 patch in 1 pouch / 3 d in 1 patch.
What NDC number is used to bill for this package of Scopolamine 1 mg/3d Patch, Extended Release?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Scopolamine 1 mg/3d 00378-6470-44 Mylan 24 patches $4.336 AB Availability likely —
scopolamine 1 mg/3d 00591-2258-04 Actavis 4 patches $4.336 AB Availability likely —
Scopolamine 1 mg/3d 42858-0150-14 Rhodes 10 patches $4.336 AB Availability likely —
Scopolamine Transdermal System 1 mg 45802-0580-01 Padagis 1 patch $4.336 AB Discontinued —
Scopolamine 1.5 mg 50742-0505-04 Ingenus 1 patch $4.336 AB Availability likely —
Scopolamine 1 mg/3d 69238-1662-02 Amneal 10 patches $4.336 AB Availability likely —
Scopolamine 1 mg/3d 70710-1846-02 Zydus 10 patches $4.336 AB Availability likely —
Transderm Scop 1 mg/3d 10019-0008-01 Baxter 1 patch — AB FDA listed —
Scopolamine 1 mg/3d 50090-5349-00 A-S 4 pouches — AB FDA listed —
scopolamine 1 mg/3d 50090-7188-00 A-S 1 d — AB FDA listed —
Scopolamine Trandermal System 1 mg 63629-8450-01 Bryant 1 patch — AB FDA listed —
Scopolamine Trandermal System 1 mg 63629-8451-01 Bryant 1 patch — AB FDA listed —
Scopolamine Trandermal System 1 mg 63629-8452-01 Bryant 1 patch — AB FDA listed —
Scopolamine 1.5 mg 68071-3994-04 NuCare 1 patch — AB FDA listed —
Scopolamine 1 mg/3dthis 70771-1787-04 Zydus 4 patches — AB FDA listed —
Scopolamine Transdermal System 1 mg 71335-2718-01 Bryant 1 patch — AB FDA listed —
Scopolamine 1 mg/3d 71335-3013-01 Bryant 4 patches — AB FDA listed —
Scopolamine 1 mg/3d 71335-3014-01 Bryant 10 patches — AB FDA listed —
Scopolamine 1 mg/3d 71335-3015-01 Bryant 24 patches — AB FDA listed —
Scopolamine Trandermal System 1 mg 72162-1419-02 Bryant 1 patch — AB FDA listed —
Scopolamine 1 mg/3d 72162-2453-02 Bryant 4 patches — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Sep 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Scopolamine Transdermal Patch inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 92RU3N3Y1O
    Dimethicone is a silicone-based oil that acts as an anti-foaming agent and lubricant in medicines. It reduces gas bubbles in liquid formulations and helps coat and protect the stomach lining when ingested.
  • UNII U725QWY32X
    Povidone K30 is a synthetic polymer made from petroleum. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the stomach so the medicine can be absorbed.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA217893 (ANDA)
Labeler code70771
First marketedSep 2024
Product typeHuman Prescription Drug
Portfolio720 products on file

More NDCs from Zydus Lifesciences Limited labeler code 70771

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 Package Label / Principal Display Panel
📄 Package Label / Principal Display Panel 21 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Scopolamine transdermal system, 1 mg/3 days Carton of 4 transdermal systems NDC 70771-1787-4 Rx only 4's carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Scopolamine — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Scopolamine. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$7.24M
Claims incl. refills
112.6K
Beneficiaries
81.9K
Spend / beneficiary
$88.40
Spend / claim
$64.29
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Scopolamine — the ingredient across all brands.

Top reported reactions

Nausea804
Vomiting549
Dizziness535
Headache410
Fatigue353
Pain330
Diarrhoea327

Age at onset

Neonate2
Infant11
Child14
Adolescent45
Adult419
Elderly157

Reporter sex

6,806 reports

Serious outcomes

Hospitalization2,181
Death788
Life-threatening365
Disabling182
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 519 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 10 patches (70771-1787-02), 24 patches (70771-1787-07). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 70771-1786-09 · Zydus 70771-1790-03 · Zydus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.